David vs. Goliath: Taiwan's PGI Wins $23M Settlement in Sequencing Patent Dispute

Taiwan's Personal Genomics (PGI) settled a seven-year patent infringement dispute with Pacific Biosciences (PacBio) for $23 million through 2029. The case centered on U.S. Patent No. 7,767,441 covering single-molecule sequencing technology used in PacBio's Sequel platforms. Despite PacBio's attempts to invalidate the patent through PTAB and Federal Circuit appeals, key claims remained valid. The settlement includes structured payments, worldwide licensing, and a covenant not to sue, providing PacBio operational certainty while validating PGI's IP strategy.